To better understand the pharmacologic underpinnings of human memory, we have pursued a """"""""pharmacologic challenge"""""""" strategy which involves attempts to model the memory of Alzheimer's disease (AD) in older volunteers (protocol 83-M-0123). After testing numerous medications, we have discovered that a combination of the nicotinic antagonist, mecamylamine, with the central muscarinic antagonist, scopolamine, has proved most effective in briefly modeling the memory impairment of AD. This data is consistent with previously published brain imaging literature, and once more emphasizes the central importance of the cholinergic system in human memory. We are also focusing on the testing of subjects """"""""at risk"""""""" for developing AD on the basis of family history and age (protocol 95-M-0096). As part of this study, we are looking for evidence of increased sensitivity to cholinergic blockade in these subjects, even before they manifest signs of cognitive decline. It is our hypothesis that this test might serve as a early diagnostic marker for the disease process. In addition, we are treating AD patients chronically with the anticholinergic scopolamine to determine if they are capable of cholinergic upregulation and increased response to cholinesterase inhibitors (protocol 95-M-0096). This study could have an immediate impact on treatment strategies with AD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Intramural Research (Z01)
Project #
1Z01MH000339-16
Application #
6162823
Study Section
Special Emphasis Panel (GPB)
Project Start
Project End
Budget Start
Budget End
Support Year
16
Fiscal Year
1997
Total Cost
Indirect Cost
Name
U.S. National Institute of Mental Health
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Huey, Edward D; Mirza, Nadeem; Putnam, Karen T et al. (2006) Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients. Dement Geriatr Cogn Disord 22:48-53
Sunderland, Trey; Hampel, Harald; Takeda, Masatoshi et al. (2006) Biomarkers in the diagnosis of Alzheimer's disease: are we ready? J Geriatr Psychiatry Neurol 19:172-9
Cohen, Robert M; Szczepanik, Joanna; McManus, Michael et al. (2006) Hippocampal atrophy in the healthy is initially linear and independent of age. Neurobiol Aging 27:1385-94
Sunderland, Trey (2006) Modern diagnostic approaches in dementia: on the cusp of change. J Geriatr Psychiatry Neurol 19:123-4
Filbey, Francesca M; Holroyd, Tom; Carver, Frederick et al. (2005) A magnetoencephalography spatiotemporal analysis of neural activities during feature binding. Neuroreport 16:1747-52
Greenwood, P M; Sunderland, Trey; Putnam, Karen et al. (2005) Scaling of visuospatial attention undergoes differential longitudinal change as a function of APOE genotype prior to old age: results from the NIMH BIOCARD study. Neuropsychology 19:830-40
Buerger, Katharina; Teipel, Stefan J; Zinkowski, Raymond et al. (2005) Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment. Neurosci Lett 391:48-50
Sunderland, Trey; Gur, Raquel E; Arnold, Steven E (2005) The use of biomarkers in the elderly: current and future challenges. Biol Psychiatry 58:272-6
Sunderland, Trey (2005) Geriatric psychiatry: coming of age in America. Biol Psychiatry 58:263-4
Greenwood, P M; Lambert, Chantal; Sunderland, Trey et al. (2005) Effects of apolipoprotein E genotype on spatial attention, working memory, and their interaction in healthy, middle-aged adults: results From the National Institute of Mental Health's BIOCARD study. Neuropsychology 19:199-211

Showing the most recent 10 out of 23 publications